Plimoth Trust Co. LLC Raises Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Plimoth Trust Co. LLC grew its stake in shares of Edwards Lifesciences Co. (NYSE:EWFree Report) by 5.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,834 shares of the medical research company’s stock after acquiring an additional 195 shares during the period. Plimoth Trust Co. LLC’s holdings in Edwards Lifesciences were worth $366,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $648,540,000. Brown Advisory Inc. boosted its stake in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after acquiring an additional 3,048,274 shares during the last quarter. CIBC Private Wealth Group LLC increased its position in Edwards Lifesciences by 197.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after purchasing an additional 2,286,119 shares in the last quarter. AustralianSuper Pty Ltd purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $168,519,000. Finally, Sands Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after purchasing an additional 1,567,526 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $91.09 on Thursday. The firm’s fifty day simple moving average is $87.99 and its 200 day simple moving average is $85.56. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The firm has a market capitalization of $54.89 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 3.38 and a beta of 1.11.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of several recent analyst reports. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. The Goldman Sachs Group initiated coverage on Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 price objective on the stock. Morgan Stanley lifted their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Barclays increased their target price on Edwards Lifesciences from $100.00 to $101.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $95.18.

Check Out Our Latest Research Report on EW

Insider Buying and Selling at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian purchased 580 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The shares were purchased at an average price of $85.74 per share, with a total value of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of the company’s stock in a transaction on Monday, May 6th. The shares were bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now directly owns 3,268 shares of the company’s stock, valued at $280,198.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders sold 90,499 shares of company stock valued at $7,866,511 over the last 90 days. 1.27% of the stock is owned by corporate insiders.

About Edwards Lifesciences

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Stories

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.